PDS Biotechnology Co. (NASDAQ:PDSB) Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC raised its holdings in shares of PDS Biotechnology Co. (NASDAQ:PDSB) by 9.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 415,113 shares of the company’s stock after purchasing an additional 37,142 shares during the period. Geode Capital Management LLC’s holdings in PDS Biotechnology were worth $1,586,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. Ground Swell Capital LLC purchased a new position in PDS Biotechnology during the 2nd quarter worth $67,000. Vontobel Holding Ltd. boosted its holdings in PDS Biotechnology by 233.3% in the third quarter. Vontobel Holding Ltd. now owns 40,000 shares of the company’s stock worth $153,000 after acquiring an additional 28,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of PDS Biotechnology during the second quarter worth about $115,000. Squarepoint Ops LLC acquired a new position in shares of PDS Biotechnology during the second quarter valued at about $120,000. Finally, XTX Topco Ltd raised its position in shares of PDS Biotechnology by 241.8% in the 3rd quarter. XTX Topco Ltd now owns 67,182 shares of the company’s stock valued at $257,000 after purchasing an additional 47,528 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

Analyst Upgrades and Downgrades

PDSB has been the topic of several research analyst reports. StockNews.com downgraded shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, November 9th. B. Riley dropped their price objective on shares of PDS Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, November 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $21.00 target price on shares of PDS Biotechnology in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PDS Biotechnology Price Performance

Shares of NASDAQ:PDSB opened at $1.57 on Thursday. PDS Biotechnology Co. has a twelve month low of $1.53 and a twelve month high of $6.68. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. The company has a market cap of $58.73 million, a PE ratio of -1.35 and a beta of 1.90. The company’s 50 day moving average is $2.18 and its 200 day moving average is $2.92.

PDS Biotechnology Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.